Share on StockTwits

Galena Biopharma (NASDAQ:GALE)‘s stock had its “buy” rating restated by equities researchers at Noble Financial in a research report issued on Wednesday, American Banking & Market News reports.

GALE has been the subject of a number of other recent research reports. Analysts at MLV & Co
cut their price target on shares of Galena Biopharma from $6.00 to $5.00 in a research note on Thursday, March 20th. Separately, analysts at Roth Capital cut their price target on shares of Galena Biopharma from $12.00 to $7.00 in a research note on Tuesday, March 18th. Finally, analysts at Cantor Fitzgerald downgraded shares of Galena Biopharma to a “sell” rating in a research note on Tuesday, March 18th. They now have a $3.00 price target on the stock, down previously from $3.50. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. Galena Biopharma currently has a consensus rating of “Buy” and an average target price of $6.31.

Shares of Galena Biopharma (NASDAQ:GALE) traded up 4.88% during mid-day trading on Wednesday, hitting $2.58. 3,931,668 shares of the company’s stock traded hands. Galena Biopharma has a 52-week low of $1.65 and a 52-week high of $7.77. The stock has a 50-day moving average of $2.3 and a 200-day moving average of $3.64. The company’s market cap is $304.1 million.

Galena Biopharma (NASDAQ:GALE) last announced its earnings results on Tuesday, May 6th. The company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.08. The company had revenue of $2.17 million for the quarter, compared to the consensus estimate of $2.09 million. On average, analysts predict that Galena Biopharma will post $-0.36 earnings per share for the current fiscal year.

Galena Biopharma, Inc (NASDAQ:GALE), formerly RXi Pharmaceuticals Corporation, incorporated on April 3, 2006, is a biotechnology company focused on discovering, developing and commercializing therapies addressing unmet medical needs using targeted biotherapeutics.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.